Gynecologic Cancer
Conference Coverage
20% with cancer on checkpoint inhibitors get thyroid dysfunction
Researchers report more than double the rate of hypothyroidism and more than triple the rate of hyperthyroidism, compared with rates in published...
From the Journals
No staff COVID-19 diagnoses after plan at Chinese cancer center
Conference Coverage
Younger gynecologic cancer patients at risk for early bone loss
Feature
COVID-19 experiences from the ob.gyn. front line
Conference Coverage
Financial toxicity is a common complication of gynecologic cancers
Feature
Maintaining cancer care in the face of COVID-19
Oncologists are moving cancer patients to other hospitals, reevaluating the need for cancer treatments, and embracing telemedicine to protect...
Conference Coverage
Barriers to clinical trial participation revealed by gynecologic cancer patients
A survey suggests a lack of discussion about clinical trials between doctors and patients with gynecologic cancers.
From the Journals
Blood test might detect multiple cancer types, study suggests
The test, which uses methylation patterns in plasma cell-free DNA, had specificity and sensitivity approaching those needed for population-based...
From the Journals
PARP inhibitors not cost effective for platinum-resistant ovarian cancer
Conference Coverage
Vaginal artesunate quells CIN 2/3 lesions, clears HPV
Self-administered treatment with the antimalarial drug artesunate was safe and effective in a small proof-of-concept study.
Opinion
‘Impressive’ SOLO3 results should influence practice
Dr. Alan P. Lyss reviews data showing that olaparib outperformed chemotherapy in patients with heavily pretreated ovarian cancer.